Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study

被引:33
作者
Andersen, J. B. [1 ]
Owe, J. F. [2 ]
Engeland, A. [3 ,4 ]
Gilhus, N. E. [1 ,2 ]
机构
[1] Univ Bergen, Dept Clin Med, Neurol Sect, N-5020 Bergen, Norway
[2] Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway
[3] Norwegian Inst Publ Hlth, Dept Pharmacoepidemiol, Div Epidemiol, Bergen, Norway
[4] Univ Bergen, Dept Global Publ Hlth & Primary Care, N-5020 Bergen, Norway
关键词
comorbidity; drug therapy; myasthenia gravis; DISEASE SEVERITY; ANTIBODIES; DISORDERS; RISK;
D O I
10.1111/ene.12439
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purpose Comorbidity in myasthenia gravis (MG) is important for diagnosis, treatment and prognosis. Disease complexity was assessed by examining total drug treatment, immune therapy and comorbidity in a complete national MG cohort. Methods All recipients of the MG-specific drug pyridostigmine 2004-2010 registered in the compulsory Norwegian Prescription Database who met the inclusion criteria were included. The pyridostigmine group was compared with the general Norwegian population. Results Myasthenia gravis patients received co-medication more often than the controls for nearly all groups of medication, including insulins (95% confidence interval 2.0-3.7), thyroid therapy (1.7-2.5), antidepressants (1.3-1.7), anti-infectives (1.2-1.4), lipid-modifying agents (1.1-1.4) and immunomodulating agents (6.8-8.8). Conclusions Myasthenia gravis patients are more often treated with non-MG prescription drugs than controls, reflecting frequent co-medication and comorbidity.
引用
收藏
页码:948 / 955
页数:8
相关论文
共 23 条
[1]   Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries [J].
Andersen, J. B. ;
Heldal, A. T. ;
Engeland, A. ;
Gilhus, N. E. .
ACTA NEUROLOGICA SCANDINAVICA, 2014, 129 :26-31
[2]   Myasthenia gravis requiring pyridostigmine treatment in a national population cohort [J].
Andersen, J. B. ;
Engeland, A. ;
Owe, J. F. ;
Gilhus, N. E. .
EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (12) :1445-1450
[3]   A national epidemiological study of Myasthenia Gravis in Australia [J].
Gattellari, M. ;
Goumas, C. ;
Worthington, J. M. .
EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 (11) :1413-1420
[4]  
Gilhus N.E., 2011, AUTOIMMUNE DIS, V2011
[5]   Myasthenia gravis in the elderly [J].
Hellmann, Mark A. ;
Mosberg-Galili, Ronit ;
Steiner, Israel .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2013, 325 (1-2) :1-5
[6]   MYASTHENIA GRAVIS: SLEEP QUALITY, QUALITY OF LIFE, AND DISEASE SEVERITY [J].
Hernandez Martinez De Lapiscina, Elena ;
Erro Aguirre, Maria Elena ;
Ayuso Blanco, Teresa ;
Jerico Pascual, Ivonne .
MUSCLE & NERVE, 2012, 46 (02) :174-180
[7]   Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care [J].
Hoff, J. M. ;
Daltveit, A. K. ;
Gilhus, N. E. .
EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 (01) :38-43
[8]   Mood and anxiety disorders in patients with myasthenia gravis - Aetiology, diagnosis and treatment [J].
Kulaksizoglu, Isin Baral .
CNS DRUGS, 2007, 21 (06) :473-481
[9]  
Lundeen Jessica, 2004, J Clin Neuromuscul Dis, V6, P9, DOI 10.1097/01.cnd.0000138445.13978.e4
[10]   Frequency of Autoimmune Diseases in Myasthenia Gravis: A Systematic Review [J].
Mao, Zhi-Feng ;
Yang, Long-Xiu ;
Mo, Xue-An ;
Qin, Chao ;
Lai, Yong-Rong ;
He, Ning-Yu ;
Li, Tong ;
Hackett, Maree L. .
INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2011, 121 (03) :121-129